Clinical Trial Update: WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the three-drug combination bosutinib, palbociclib, and fulvestrant for HR-positive, HER2-negative metastatic breast cancer refractory…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• BOSULIF (bosutinib)
• Faslodex (fulvestrant)
• IBRANCE (PALBOCICLIB)

Snippet

Sponsor: Georgetown University | Conditions: Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Phase 1 | Status: COMPLETED